Recent Findings from University of Bari 'Aldo Moro' Has Provided New Information about Lymphoma (Combining Brentuximab Vedotin With Dexamethasone, High-dose Cytarabine, and Cisplatin As Salvage Treatment In Pediatric Relapsed or Refractory...).

A recent study conducted at the University of Bari 'Aldo Moro' in Italy has provided new information about the treatment of lymphoma in pediatric patients. The study focused on two boys with aggressive and high-risk relapsed Hodgkin lymphoma (HL) who were successfully treated with a combination of brentuximab vedotin (BV), dexamethasone, high-dose cytarabine, and cisplatin. The researchers concluded that this combination therapy could be an effective first-line salvage treatment for relapsed or refractory HL in pediatric patients. This study expands the current therapeutic options for treating this type of lymphoma. [Extracted from the article]